Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,653 across all filing types
Latest filing 2024-01-02 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于公司与天广实签署《合作协议之补充协议》暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by 贝达药业股份有限公司 regarding the signing of a supplementary cooperation agreement with 北京天广实生物技术股份有限公司, which constitutes a related party transaction. It details the transaction terms, pricing, payment, and the impact on the company. The document references compliance with Shenzhen Stock Exchange listing rules and internal governance procedures. It does not contain financial statements or comprehensive financial data but rather focuses on the disclosure of a specific transaction and its regulatory compliance. The document length is 4418 characters, which is relatively short and typical for an announcement. This fits the profile of a Regulatory Filing (RNS) as it is a regulatory announcement about a related party transaction and not a full financial report or other specific filing type.
2024-01-02 Chinese
关于调整2023年限制性股票激励计划首次授予激励对象名单及授予数量的公告
Board/Management Information Classification · 95% confidence The document is an official announcement from a company regarding adjustments to the 2023 restricted stock incentive plan, specifically about the first grant of restricted stock to incentive recipients. It details changes in the number of recipients and shares granted, approvals by the board and supervisory committees, legal opinions, and independent financial advisor reports. The content focuses on corporate governance and management decisions related to stock incentives rather than financial results, earnings, or regulatory filings. It is not a full annual or interim report, nor an earnings release or audit report. It is also not a proxy solicitation or voting results announcement. The document is a formal announcement about management decisions on stock incentive plans, which fits best under Board/Management Information (MANG) as it relates to management-level decisions and disclosures about stock incentives and board approvals.
2023-12-26 Chinese
第四届监事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the ninth meeting of the fourth Supervisory Board of Betta Pharmaceuticals Co., Ltd. It details the meeting's convening, attendance, and the approval of adjustments to the 2023 restricted stock incentive plan, including the number of shares and recipients. The document also references related announcements published separately on the CNINFO website. The content focuses on board-level decisions and approvals related to stock incentive plans, which is typical of Board/Management Information filings. The document is relatively short (1863 characters) and does not contain financial statements or detailed financial data, so it is not an Annual Report or Interim Report. It is not a voting result announcement since it reports on board resolutions rather than shareholder votes. Therefore, the appropriate classification is Board/Management Information (MANG).
2023-12-26 Chinese
上海荣正企业咨询服务（集团）股份有限公司关于贝达药业股份有限公司2023年限制性股票激励计划调整及首次授予相关事项之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" related to the 2023 restricted stock incentive plan adjustment and initial grant for Betta Pharmaceuticals Co., Ltd. It is issued by Shanghai Rongzheng Enterprise Consulting Services (Group) Co., Ltd. The content includes detailed explanations of the stock incentive plan, approval processes, grant conditions, and financial impacts. It is a standalone advisory report focusing on a specific equity incentive plan, not a full annual or quarterly financial report. It does not contain comprehensive financial statements or earnings data but provides an independent financial advisor's opinion on the stock incentive plan. This fits the definition of an Audit Report / Information (AR) as it is a standalone report related to financial advisory and compliance matters, not a full annual report or earnings release. The document length (over 10,000 characters) and detailed content confirm it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence.
2023-12-26 Chinese
第四届董事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the 10th meeting of the 4th Board of Directors of Betta Pharmaceuticals Co., Ltd. It details the approval of adjustments to the 2023 restricted stock incentive plan and the granting of restricted stock to incentive recipients. The document includes meeting attendance, voting results, and references to related announcements and legal opinions. It does not contain financial statements or detailed financial performance data. It is a formal disclosure of board decisions related to stock incentives, which falls under Board/Management Information (MANG). The document length is about 2033 characters, indicating it is a concise announcement rather than a full report.
2023-12-26 Chinese
监事会关于公司2023年限制性股票激励计划首次授予激励对象名单（授予日）的核查意见
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from the supervisory board regarding the verification opinion on the initial grant list of the 2023 restricted stock incentive plan for the company. It discusses compliance with relevant laws and regulations, adjustments to the number of shares and recipients, and confirms the grant date and price. The content focuses on stock incentive plan details and supervisory board approval, which aligns with announcements related to share issues or capital changes rather than a full financial report or management discussion. The document length is short (1413 characters) and it is a formal announcement of a stock incentive grant, fitting the category of Share Issue/Capital Change (SHA).
2023-12-26 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.